These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16840725)

  • 1. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
    Corbacioglu S; Kilic M; Westhoff MA; Reinhardt D; Fulda S; Debatin KM
    Blood; 2006 Nov; 108(10):3504-13. PubMed ID: 16840725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
    Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
    Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
    Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
    Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
    Hirota S; Ohashi A; Nishida T; Isozaki K; Kinoshita K; Shinomura Y; Kitamura Y
    Gastroenterology; 2003 Sep; 125(3):660-7. PubMed ID: 12949711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
    Tickenbrock L; Hehn S; Sargin B; Evers G; Ng PR; Choudhary C; Berdel WE; Müller-Tidow C; Serve H
    Int J Hematol; 2008 Sep; 88(2):174-180. PubMed ID: 18668305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.
    Zheng R; Klang K; Gorin NC; Small D
    Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.
    Nakai M; Hashikura Y; Ohkouchi M; Yamamura M; Akiyama T; Shiba K; Kajimoto N; Tsukamoto Y; Hao H; Isozaki K; Hirai T; Hirota S
    Lab Invest; 2012 Mar; 92(3):451-7. PubMed ID: 22083669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
    Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
    Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.